Below is Validea's ETF fundamental report for Vanguard Value ETF (VTV). The report looks at VTV's exposure to the major investing factors including value, quality, momentum and low volatility.

HIGH POINT, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company, today announced the appointment of Michael Tung, M.D., MBA as Executive ...

Biography: VTV Ganesh is an Indian actor, comedian, and film producer primarily active in the Tamil film industry. He was born on December 21, 1961, in Chennai, Tamil Nadu, India. Ganesh started ...

The multi-year, market-crushing rally from a handful of growth stocks may finally be out of gas. For the first time in a while, the economic backdrop may finally be working in value stocks ...

Thanh Thuy remains the key attacker for VTV Binh Dien Long An. After finishing second in Group C, VTV Binh Dien Long An faced Kaohsiung Taipower (Taiwan - China) in the quarterfinals. Coach Thai Quang ...

10am – Saipa Tehran VC vs VTV Bình Điền Long An (Pool C) 1pm – Al Nassr Club vs Zhetysu VC (Pool A) 4pm – PLDT High Speed Hitters vs Nakhon Ratchasima Qmin C VC (Pool D) 7pm – Hip ...

Talking about coming together with Silambarasan for a feature film for the first time since the Gautham Vasudev Menon directorial, Trisha said, “Many have been asking about when Simbu and I would be ...

Cheap, broad exposure to large-value stocks. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform a relevant index, or most peers, over a market ...

Value Stocks Gain Ground As Inflation, Recession Fears Grow: 4 ETFs To Capitalize On The Trend Value stocks are outperforming flashy growth rivals due to market uncertainty, making value-based ...

CATT1 Phase 3 trial expected to resume following submission of protocol amendment shortening the overall duration of the trial from 12 to 6 months HIGH POINT, N.C., March 17, 2025 (GLOBE NEWSWIRE) -- ...

Shares of vTv Therapeutics rose after the Food and Drug Administration lifted a clinical hold on its diabetes treatment program. The stock gained 40% to $20.78 Monday morning. Shares have climbed ...